Quantcast

Latest Biologic Stories

2014-06-04 08:33:48

WASHINGTON, June 4, 2014 /PRNewswire-USNewswire/ -- In a letter submitted today to the U.S. Food and Drug Administration (FDA), the National Organization for Rare Disorders (NORD) urged Commissioner Margaret Hamburg to give serious consideration to the concerns of the rare disease community when setting policy regarding official names for biologics, including biosimilars. With over 7,000 rare diseases identified and 30 million Americans affected, the patient population represented by NORD is...

2014-06-04 08:29:36

MUMBAI and LA CHAUX-DE-FONDS, Switzerland, June 4, 2014 /PRNewswire/ -- - State-of-the-art Manufacturing Facility for Supply of Clinical Trial Material - With the Facility Glenmark has end-to-end Capabilities for the Development of Novel, State-of-the-art Monoclonal Antibodies Including Bi-specific Antibodies Glenmark Pharmaceuticals S.A (GPSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, India (GPL), announced the opening of its new cGMP...

2014-06-03 12:37:05

As Many as a Quarter of Specialists' Severe Persistent Asthma Patients are Refractory to Current Treatment, According to Findings from Decision Resources Group BURLINGTON, Mass., June 3, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed physician specialists will welcome the proliferation of asthma therapies that are poised for U.S. launch by 2018, and they anticipate utilizing more convenient once-daily therapies and novel biological agents to manage their asthmatic patients....

2014-06-02 08:31:48

CRANBURY, N.J., June 2, 2014 /PRNewswire/ -- Ipca Laboratories Ltd., India (Ipca) and Oncobiologics, Inc., USA (Oncobiologics) announced today the creation of a two-part alliance for the development, manufacture and commercialization of biosimilar monoclonal antibody products. Under the first part of the agreement, Ipca will in-license and commercialize biosimilar products for the India and associated markets. These products will be developed by Oncobiologics to US FDA and EU...

2014-06-01 23:01:09

LifeScienceIndustryResearch.com adds Latest Report on “Frontier Pharma: Psoriasis – Identifying and Commercializing First-in-Class Innovation” to its store. Dallas, TX (PRWEB) June 01, 2014 Psoriasis is a chronic, inflammatory disease triggered by deregulated Thymus-derived (T) cells, resulting inflammation and benign hyperplasia of keratinocytes within the skin. Manifestations of affected skin are red, thickened plaques with an overlying silver-white scale, which significantly...

2014-05-29 20:23:02

COSTA MESA, Calif., May 29, 2014 /PRNewswire/ -- DaVinci Biosciences, LLC announced today that their paper on "Human Prenatal Intestine Cells as a Valuable Source of Stem Cells and Epithelial Cells; Phenotypic and Functional Characterization" has been accepted for publication in the peer-reviewed journal CELL & TISSUE TRANSPLANTATION & THERAPY. With the current move by researchers and governments to reduce the use of animals in drug development and testing, scientists are...

2014-05-27 23:13:40

In an upcoming webinar from Atlantic Information Services, participants will learn how to manage specialty drug coupons without compromising patient access. Washington, DC (PRWEB) May 27, 2014 As the biologics pipeline continues to grow and patients face increasing specialty copays, co-insurance and maximum out-of-pocket limits, manufacturer-offered specialty drug coupons are becoming more commonplace. And with biosimilars soon entering the market, it will be critical for payers to...

2014-05-22 23:14:04

Mind-sharing Among Industry Leaders Included Case Studies, High Throughput Lab Tour, and Strategic Discussions Sunnyvale, CA (PRWEB) May 22, 2014 Freeslate, Inc., the leading provider of high throughput research solutions for biopharmaceutical development, today announced highlights of its Biologics Formulation Summit held May 20 - 21, 2014 at Janssen Pharmaceutical in Malvern, Pennsylvania. The meeting featured a tour of the Janssen high throughput lab, customer case studies, and...

2014-05-20 16:26:18

ROCKVILLE, Md., May 20, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the 3(rd) Annual Marcum LLP MicroCap Conference on Thursday, May 29, 2014 in New York City at the Grand Hyatt Hotel. Mr. Riley is scheduled to present at 4:30 p.m. (Eastern Time)....

2014-05-19 16:24:15

NEUDORF SPECIAL ECONOMIC ZONE, ST. PETERSBURG, Russia, May 19, 2014 /PRNewswire/ -- Head of the Russian Government Dmitri Medvedev visited today CJSC BIOCAD's [http://www.biocad.ru/en/we ] commercial manufacturing facility for mAb-based therapeutic proteins. This private facility is unique in Russia and Easter Europe. It produces monoclonal antibodies-based APIs for biological products that are widely used in treating oncological and autoimmune disorders. The visit occurred in...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related